GO-012
A Phase 1 SARS-CoV-2 Vaccine Study to Assess the Safety and Tolerability of GRT-R912 or GRT-R914 Administered as Prime and/or Boost in Healthy Adult Volunteers Naïve to SARS-CoV-2, SARS-CoV-2 Convalescent Subjects, and People Living with HIV.
Rationale
This Phase 1 clinical trial will assess the potential of Gritstone’s second-generation COVID-19 vaccines to generate B-cell and T-cell responses against SARS-CoV-2 in both PLWH and HIV negative subjects, in subjects who have previously been infected by SARS-CoV-2, and those who have neither been infected with nor vaccinated against SARS-CoV-2. GRT-R912 and GRTR914 are vaccines using a SAM vector based on proteins from the Venezuelan Equine Encephalitis (VEE) virus in a homologous prime-boost regimen, providing an option for a potent, single-modality approach. Gritstone has optimized the vector cassettes tailored to SARSCoV-2, specifically the beta variant, and designed them to induce balanced T-cell and antibody responses.
Investigators
- Dr Mrinmayee Dhar, Principal Investigator
- Dr Faeezah Patel
- Dr Elizea Horne
- Dr Muneerah Khan
- Dr Jeanne Coetzee
- Prof Lee Fairlie
- Tiffany Seef
- Othusitse Segalo
Latest Update
December 2023
For more about GO-012 please email rhicomms@wrhi.ac.za